Here we focus on the direct AMPK activators PT1, A-769662, ZLN024, and C24, originally identified in high throughput screens for small molecule activators of AMPK to treat diabetes, obesity and metabolic syndrome. Here, PRKAA1 is linked to obesity disorder.